Ankrin Therapeutics ApS: Financial statements 2023
CVR: 39788705
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Ankrin Therapeutics ApS (CVR 39788705) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -497,960 and a net result of DKK -2,334,458 compared with DKK -2,732,702 the year before. Equity in the 2023 report amounted to DKK -6,779,478. The company had 1 employee in the financial year.
- Gross Profit
- DKK -497,960
- Profit/Loss
- DKK -2,334,458
- Equity
- DKK -6,779,478
- Total Assets
- DKK 1,614,457
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -498 t. | -2.3 mio. | -6.8 mio. | 1 |
| 2022 | - | -1 mio. | -2.7 mio. | -4.4 mio. | 2 |
| 2021 | - | -2.4 mio. | -4.5 mio. | -1.7 mio. | 3 |
| 2020 | - | -2.1 mio. | -3.5 mio. | 2.8 mio. | 2 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Ankrin Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -1,024,945, and the net result was DKK -2,732,702.
About Ankrin Therapeutics ApS
Ankrin Therapeutics ApS was a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2018. The company has been dissolved on 5 December 2025. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Ankrin Therapeutics IvS. The company has 4 employees (2024). In 2023, the company reported a gross profit of DKK -497,960 and a net result of DKK -2,334,458 compared with DKK -2,732,702 the year before. Equity in the 2023 report amounted to DKK -6,779,478.